Heterocyclic compound as well as pharmaceutical composition and application thereof

CN120500487APending Publication Date: 2025-08-15SHANGHAI ALLIST PHARM CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202480007073.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-29
Filing Date
2024-01-18
Publication Date
2025-08-15

AI Technical Summary

Technical Problem

KRAS mutant inhibitors in the existing technology have a single structure and cannot effectively inhibit multiple KRAS mutant forms, resulting in the lack of effective treatments for more than 85% of KRAS mutant cancers.

Method used

A heterocyclic compound is provided that has inhibitory activity against cells containing KRAS mutations, can effectively inhibit cell proliferation of KRAS G12C, G12D, G12V and other mutant forms, and is suitable for various KRAS mutants.

Benefits of technology

The compound can significantly inhibit cell proliferation of KRAS G12C, G12D, G12V and other mutated forms, filling the gap in the existing technology for treating KRAS mutated cancers and providing a wider therapeutic potential.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a heterocyclic compound as well as a pharmaceutical composition and application thereof. Specifically, the present invention discloses a heterocyclic compound represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof. The compound provided by the invention has inhibitory activity on proliferation of one or more of stably transfected cells Ba / F3 KRAS G12C, Ba / F3 KRAS G12D, Ba / F3 KRAS G12V, human pancreatic cancer cells Capan-1, human non-small cell lung cancer cells NCI-H358 (KRAS G12C mutation) and human metastatic pancreatic adenocarcinoma cells AsPC-1 (KRAS G12D mutation) containing KRAS mutation, or the compound provided by the invention has relatively weak inhibitory activity on proliferation of wild PC-9 cells of KRAS. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art